Madrigal Pharmaceuticals, Inc.

MDGL

$514.50

Updated: 25/09/2026, 15:42:56

Market Cap

$11.88B

Sector

Healthcare

Industry

Biotechnology

Country

Stock valuation chart

One-year closing share-price history for MDGL

Company Profile

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.

USD

NASDAQ

CEO: William J. Sibold

Employees: 915

https://www.madrigalpharma.com

Asset Summaries

Latest generated summaries for MDGL

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for MDGL.

Share price: $514.50
Market cap: $11.88B
Exchange: NASDAQ
Currency: USD
CEO: William J. Sibold
Employees: 915
IPO date: 06/02/2007
Beta: -0.99
Last dividend: $0.00
Day range: $511.99 – $518.27
52-week range: $393.61 – $615.00
1-day performance: 0.25%
1-year performance: 30.71%
Current drawdown (1Y): -16.34%
CIK: 0001157601
CUSIP: 558868105
ISIN: US5588681057
Created: 07/12/2025, 05:12:15
Last update: 25/09/2026, 15:42:56

Track Madrigal Pharmaceuticals, Inc. with an AI analyst

See which prediction-market events move MDGL, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to MDGL from your Railway `news_articles` table.

Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 10/06/2026, 16:22:23

Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up

Zacks Investment Research • STOCK • 07/05/2026, 14:35:12

Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 06/05/2026, 16:01:20

Madrigal Pharmaceuticals: Boom Or Bust In MASH? Regretfully, I'm Bearish

Seeking Alpha • STOCK • 28/04/2026, 16:27:46

Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains?

Zacks Investment Research • STOCK • 27/03/2026, 11:06:10

Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down

Zacks Investment Research • STOCK • 20/02/2026, 12:01:11

Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2025 Earnings Call Transcript

Seeking Alpha • STOCK • 19/02/2026, 12:45:07

Madrigal (MDGL) Reports Q4 Loss, Beats Revenue Estimates

Zacks Investment Research • STOCK • 19/02/2026, 10:16:13

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results

GlobeNewsWire • STOCK • 19/02/2026, 08:00:00